Enzyme News and Research

RSS

Chemists adopt new approach to optimise enzyme for practical applications

Engineers are unlikely to tinker with the cooling system if they want to increase the size of an engine. Yet chemists at the Max Planck Institute for Coal Research have adopted an approach similar to this in their efforts to optimise an enzyme for practical applications. They

16 Feb 2010

Researchers use model organism to test new therapies for retinal degeneration

Research by Johns Hopkins sensory biologists studying fruit flies, has revealed a critical step in fly vision. Humans with problems in this same step suffer retinal dystrophies, which manifest as visual defects ranging from mild visual impairments to complete blindness.

16 Feb 2010

TB's mechanism to evade body's immune system identified

Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

16 Feb 2010

Use of non-steroidal anti-inflammatory drugs not associated with risk of squamous cell skin cancer

Contrary to previous hypotheses, the use of non-steroidal anti-inflammatory drugs does not appear associated with risk of squamous cell skin cancer, according to a report posted online today that will appear in the April print issue of Archives of Dermatology, one of the JAMA/Archives journals.

16 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Researchers discover chemical compound to combat malaria and bacterial diseases

Researchers report that they have discovered - and now know how to exploit - an unusual chemical reaction mechanism that allows malaria parasites and many disease-causing bacteria to survive. The research team, from the University of Illinois, also has developed the first potent inhibitor of this chemical reaction.

16 Feb 2010

Research findings may open door to new therapeutic strategies for serious health problems

Drugs that target the way cells convert nutrients into energy could offer new approaches to treating a range of conditions including heart attack and stroke. Using a new way to screen for potential drugs, a team led by Massachusetts General Hospital (MGH) researchers has identified several FDA-approved agents, including an over-the-counter anti-nausea drug, that can shift cellular energy metabolism processes in animals.

15 Feb 2010

Muscle-preserving therapy development may help young men keep muscle shirts a bit longer

Hey guys, remember the muscle shirts we wore in our teens and 20s? After the age of 40 that meager part of our wardrobes usually is obsolete. Yes, at the big 4-0 we begin to lose muscle, and by age 80 up to a third of it may be gone. It's an inevitable process of aging called sarcopenia.

15 Feb 2010

Researchers identify defective signaling pathway that contributes to the severity of cystic fibrosis

In a study that could lead to new therapeutic targets for patients with the cystic fibrosis, a research team from the University of California, San Diego School of Medicine has identified a defective signaling pathway that contributes to disease severity.

15 Feb 2010

Genencor launches Accellerase DUET at the 15th Annual National Ethanol Conference in Orlando

Genencor, a division of Danisco A/S, today introduced Accellerase® DUET at the Renewable Fuels Association's 15th Annual National Ethanol Conference in Orlando, Fla. This product is the latest generation in the company's line of enzymes used to convert biomass into sugars, a critical step in the production of cellulosic ethanol and other advanced biofuels and biochemicals from non-food feedstocks.

15 Feb 2010

SRC-3 gene sends signal to cell membrane to promote cell motility

The master gene called SRC-3 (steroid receptor coactivator 3) not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement - a key element of cancer spread or metastasis, said Baylor College of Medicine (www.bcm.edu) researchers and collaborators in a report that appears in the current issue of the journal Molecular Cell.

15 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

Fourth-quarter and full-year 2009 results announced by Quidel

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2009.

12 Feb 2010

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.

11 Feb 2010

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.

11 Feb 2010

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

Principio Inc., a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, today announced that the Company has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

11 Feb 2010

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Glissandra Skincare™ Inc., dedicated to the research, development, and manufacturing of anti-aging skincare products, announced it has signed its first distributorship agreement granting Enchanted Meadow the rights to distribute Glissandra to its more than 2000 spa and gift industry retailers throughout the US and Canada.

10 Feb 2010

Enzyme News and Research

Chemists adopt new approach to optimise enzyme for practical applications

Researchers use model organism to test new therapies for retinal degeneration

TB's mechanism to evade body's immune system identified

Use of non-steroidal anti-inflammatory drugs not associated with risk of squamous cell skin cancer

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Researchers discover chemical compound to combat malaria and bacterial diseases

Research findings may open door to new therapeutic strategies for serious health problems

Muscle-preserving therapy development may help young men keep muscle shirts a bit longer

Researchers identify defective signaling pathway that contributes to the severity of cystic fibrosis

Genencor launches Accellerase DUET at the 15th Annual National Ethanol Conference in Orlando

SRC-3 gene sends signal to cell membrane to promote cell motility

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Researchers identify potential drug candidate that halts tumor growth

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Fourth-quarter and full-year 2009 results announced by Quidel

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Understanding the DNA Damage Response in Innate Immunity eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo